These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1688516)

  • 1. A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Crawford SM; Bagshawe KD; Carruthers L
    Cancer Chemother Pharmacol; 1990; 25(4):291-4. PubMed ID: 1688516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
    Grunberg SM; Stevenson LL; Russell CA; McDermed JE
    J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M; Droz JP; Pouillart P; Paule B; Brion N; Bons J
    Cancer Chemother Pharmacol; 1989; 23(6):389-91. PubMed ID: 2523762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.
    Kris MG; Gralla RJ; Clark RA; Tyson LB
    J Natl Cancer Inst; 1989 Jan; 81(1):42-6. PubMed ID: 2521184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
    Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
    J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
    Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
    Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.
    Smith DB; Newlands ES; Rustin GJ; Begent RH; Howells N; McQuade B; Bagshawe KD
    Lancet; 1991 Aug; 338(8765):487-90. PubMed ID: 1714532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
    Green JA; Watkin SW; Hammond P; Griggs J; Challoner T
    Cancer Chemother Pharmacol; 1989; 24(2):137-9. PubMed ID: 2525078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trials of ondansetron with high-dose cisplatin.
    Kris MG
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):23-7. PubMed ID: 1387247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
    Khojasteh A; Sartiano G; Tapazoglou E; Lester E; Gandara D; Bernard S; Finn A
    Cancer; 1990 Sep; 66(6):1101-5. PubMed ID: 2144788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
    Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
    Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.
    de Haan LD; de Mulder PH; Beex LV; Debruyne FM; Challoner T; de Pauw BE
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1383-4. PubMed ID: 2972545
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
    J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy.
    Tsavaris N; Fountzilas G; Mylonakis N; Athanassiadis A; Kosmas C; Karakousis C; Bacoyiannis C; Kosmidis P
    Oncology; 1998; 55(6):513-6. PubMed ID: 9778615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.